The global point of care diagnostics market size was valued at USD 50.17 billion in 2025 and is projected to grow from USD 53.52 billion in 2026 to USD 89.71 billion by 2034, registering a CAGR of 6.67% during the forecast period from 2026 to 2034. North America dominated the point of care diagnostics market with a market share of 42.35% in 2025.
The rising frequency of infectious illnesses and chronic ailments, such as cardiovascular diseases, cancer, diabetes, etc., along with infectious diseases like HIV/AIDS, malaria, and others, has increased the demand for point-of-care testing. Furthermore, technological advancements in the point-of-care diagnostic technique are estimated to create opportunities for global market growth.
Point of Care Diagnostics (POC Diagnostics) refers to medical testing conducted at or near the site of patient care. These diagnostic tools provide immediate results, enabling rapid decision-making and timely treatment. POC diagnostics encompass a wide range of tests, including blood glucose monitoring, pregnancy tests, infectious disease detection, and more. These tests are designed for use in various settings such as hospitals, clinics, and even at home.
Download a Free Sample To learn more about this report,
Molecular Testing Is Moving Closer to the Patient
The Point of Care Diagnostics Market is shifting toward compact molecular systems that bring laboratory-quality testing into clinics, urgent-care centers, and other decentralized settings. PCR-based point-of-care platforms can identify infections during the same visit, helping clinicians make treatment decisions without waiting for samples to return from centralized laboratories. New systems are also combining several pathogens in one test, increasing clinical value while reducing separate testing steps. This trend expands point-of-care diagnostics beyond traditional glucose meters and lateral-flow tests into higher-value molecular applications. It creates demand for compact analyzers, multiplex assays, automated sample processing, and connected reporting systems capable of delivering accurate results with limited laboratory infrastructure.
In January 2025, Roche received U.S. FDA clearance and CLIA waivers for cobas liat STI multiplex assays that use PCR technology and provide results in about 20 minutes.
Faster Clinical Decisions Are Driving Near-Patient Testing
The need for faster diagnosis is a major driver because sending samples to centralized laboratories can delay treatment decisions, referrals, and patient management. Point-of-care systems shorten this pathway by generating results near the patient, allowing clinicians to connect diagnosis and treatment more closely. WHO states that point-of-care testing can improve treatment decision-making, avoid referrals, increase healthcare efficiency, and reduce costs, particularly where laboratory infrastructure is weak. These advantages support adoption across infectious disease, diabetes, cardiovascular testing, pregnancy testing, coagulation, and other clinical areas. The driver is especially strong in primary and community care, where rapid results can reduce dependence on large centralized diagnostic facilities.
In May 2026, WHO reported that more than half of the world's population still lacked access to basic diagnostic services, highlighting the need for more decentralized testing capacity.
Regulatory Evidence Requirements Can Slow New Test Deployment
Point-of-care tests must be simple to operate without sacrificing accuracy, creating a significant regulatory barrier for manufacturers. In the United States, tests are categorized according to complexity, and manufacturers seeking CLIA-waived status for applicable moderate-complexity products must provide scientifically valid evidence that statutory waiver criteria are satisfied. This means companies may need additional flex studies, clinical studies, usability evidence, and documentation after obtaining initial marketing authorization. These requirements protect patients but can increase development costs and extend commercialization timelines. The challenge is particularly important for smaller diagnostic companies that need to fund both technology development and extensive validation before accessing the broad decentralized settings where waived tests can be used.
In March 2026, the FDA granted a CLIA waiver to Lumos Diagnostics' FebriDx Bacterial/Non-Bacterial Assay after reviewing evidence supporting its use as a waived test system.
Local Manufacturing Can Expand Diagnostics in Underserved Regions
Local production creates a major opportunity for point-of-care diagnostics because many countries with limited laboratory infrastructure also depend heavily on imported tests. Technology transfer can help establish regional manufacturing, shorten supply chains, build technical capability, and improve preparedness for disease outbreaks. Rapid tests are especially suitable because many require little additional equipment and can be deployed in smaller health facilities. Expanding production in underserved regions could therefore create new markets for diagnostic components, manufacturing equipment, quality systems, and finished tests. The opportunity is not limited to one disease because adaptable rapid-test platforms can potentially support HIV, malaria, syphilis, and other infectious-disease programs as healthcare needs change.
In May 2025, WHO and Medicines Patent Pool announced a sublicense enabling Nigeria-based Codix Bio to develop and manufacture rapid tests using SD Biosensor technology, initially focusing on HIV.
Usability and Accessibility Must Improve as Testing Moves Outside Laboratories
A major challenge is ensuring that rapid tests remain easy and reliable for people with different physical abilities, literacy levels, and testing experience. As diagnostics move from trained laboratories into clinics, pharmacies, community settings, and homes, product design becomes as important as analytical performance. Small text, confusing symbols, difficult packaging, and complicated sample-handling steps can prevent users from completing tests correctly. Manufacturers therefore need to consider accessible instructions, readable displays, intuitive components, and inclusive product design. Addressing these requirements can increase development work, but failure to do so may restrict adoption among older adults, people with disabilities, and other populations that could benefit significantly from decentralized diagnostics.
In October 2025, WHO formally launched its first rapid-diagnostic-test accessibility guidance, providing recommendations for manufacturers developing professional-use and self-test products.
Infectious Diseases Testing Kits is Projected to Register the Fastest Growth at a CAGR of 8.34%
The infectious diseases testing kits segment is projected to register the fastest growth in the point of care diagnostics market at a CAGR of 8.34% during the forecast period, driven by increasing demand for rapid and accessible testing for infectious conditions. Point-of-care infectious disease tests enable faster identification of infections and support timely clinical decision-making without relying entirely on centralized laboratories. Growing awareness of early disease detection, increasing availability of rapid molecular and immunoassay technologies, and rising demand for decentralized diagnostic services across hospitals, clinics, pharmacies, and community healthcare settings continue to support segment growth.
Request Customizationto receive a tailored report.
OTC Based Devices is Projected to Register the Fastest Growth at a CAGR of 7.91%
The OTC based devices segment is projected to register the fastest growth in the point of care diagnostics market at a CAGR of 7.91% during the forecast period, supported by increasing consumer preference for convenient, accessible, and self-administered diagnostic solutions. OTC diagnostic devices allow individuals to conduct selected health tests without requiring a prescription or visiting a conventional diagnostic facility. Growing awareness of preventive healthcare, expansion of home-based testing, improvements in user-friendly diagnostic technologies, and increasing availability of testing products through retail and digital channels continue to strengthen demand for OTC based devices.
Home Care is Projected to Register the Fastest Growth at a CAGR of 8.22%
The home care segment is projected to register the fastest growth in the point of care diagnostics market at a CAGR of 8.22% during the forecast period, driven by increasing adoption of self-testing and remote health monitoring solutions. Point-of-care diagnostic devices enable patients to perform selected tests conveniently at home, reducing dependence on frequent hospital or laboratory visits. Increasing emphasis on preventive healthcare, growing adoption of digital health technologies, rising availability of easy-to-use diagnostic kits, and increasing demand for decentralized healthcare services continue to support the expansion of point-of-care diagnostics in home care settings.
Speak to an Analystto discuss market opportunities.
North America dominated the point of care diagnostics market with the largest 42.35% market share in 2025, representing a market value of USD 21.25 billion. The region is projected to grow at a CAGR of 6.82% during the forecast period. Its leadership is supported by advanced healthcare infrastructure, widespread adoption of rapid diagnostic technologies, strong presence of diagnostic companies, and growing demand for decentralized testing. Point of care diagnostics are increasingly used across hospitals, clinics, emergency departments, pharmacies, and home-care settings to provide faster clinical information and support timely treatment decisions. Increasing adoption of portable and connected diagnostic platforms is further improving accessibility. Continued healthcare innovation strengthens North America's position in the global point of care diagnostics market.
The United States is an important contributor to the point of care diagnostics market due to its sophisticated healthcare system, extensive diagnostic laboratory ecosystem, strong medical technology industry, and widespread adoption of rapid testing solutions. Healthcare providers use point of care technologies for glucose monitoring, infectious disease testing, cardiac assessment, coagulation testing, pregnancy testing, and other clinical applications. Growing emphasis on rapid diagnosis and decentralized healthcare is encouraging adoption across hospitals, physician offices, urgent-care facilities, pharmacies, and home settings. Development of compact analyzers, connected diagnostic devices, and digital health platforms is further expanding applications. Continued investment in diagnostic innovation supports development of the country's point of care diagnostics market.
Canada contributes to the point of care diagnostics market through its established healthcare system, increasing adoption of decentralized testing, and growing emphasis on improving diagnostic accessibility across geographically dispersed communities. Portable diagnostic technologies can support healthcare delivery in hospitals, clinics, pharmacies, remote communities, and home-care environments by reducing dependence on centralized laboratories for selected tests. Increasing demand for rapid infectious disease testing, chronic disease monitoring, and emergency diagnostics is supporting adoption. Integration of connected medical devices and digital health systems is also improving the management of diagnostic information. Continued modernization of healthcare delivery and expansion of community-based services support long-term development of Canada's point of care diagnostics market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the point of care diagnostics market and is expected to expand at a CAGR of 8.96% during the forecast period. The region accounted for 21.8% of the global market in 2025, representing a market value of USD 10.94 billion. Growth is supported by expanding healthcare infrastructure, large patient populations, increasing prevalence of chronic and infectious diseases, and growing demand for accessible diagnostic services. Point of care technologies provide opportunities to extend testing beyond centralized laboratories and improve diagnostic availability across urban and underserved areas. Rising healthcare expenditure and development of domestic diagnostic manufacturing capabilities are also supporting adoption. These developments support strong expansion of the point of care diagnostics market across Asia Pacific.
Japan is an important contributor to the point of care diagnostics market through its sophisticated healthcare infrastructure, advanced medical technology industry, aging population, and strong adoption of diagnostic technologies. Point of care devices are used to support rapid testing and disease monitoring across hospitals, clinics, emergency care, and home-based healthcare environments. Growing requirements for efficient chronic disease management are encouraging adoption of compact and user-friendly diagnostic systems. Japan's expertise in electronics, sensors, miniaturization, and medical devices also supports development of increasingly sophisticated testing platforms. Integration of diagnostic technologies with digital healthcare systems further improves clinical workflows. Continued medical technology innovation strengthens Japan's contribution to the Asia Pacific point of care diagnostics market.
China plays a significant role in the point of care diagnostics market due to its large population, expanding healthcare infrastructure, growing diagnostic industry, and increasing demand for rapid and accessible testing services. Hospitals, community health centers, clinics, and other healthcare facilities are adopting point of care technologies for infectious disease detection, glucose monitoring, cardiac testing, and other applications. Expansion of healthcare services beyond major metropolitan areas is creating opportunities for portable diagnostic platforms that can provide results without sophisticated centralized laboratory infrastructure. Domestic manufacturers are also strengthening capabilities in diagnostic devices and test kits. Continued healthcare modernization reinforces China's importance within the Asia Pacific point of care diagnostics market.
Europe accounted for 27.15% of the global point of care diagnostics market in 2025, reaching a market value of USD 13.62 billion. The region is anticipated to grow at a CAGR of 6.54% during the forecast period. Market development is supported by established healthcare systems, growing adoption of decentralized testing, increasing chronic disease management requirements, and continued innovation in medical diagnostics. Point of care testing enables healthcare professionals to obtain rapid diagnostic information across hospitals, clinics, emergency settings, and community healthcare facilities. Development of connected analyzers and portable diagnostic platforms is further improving clinical workflow efficiency. Increasing emphasis on accessible and timely testing supports expansion of the point of care diagnostics market across Europe.
Germany is an important contributor to the point of care diagnostics market in Europe due to its advanced healthcare infrastructure, strong medical device industry, extensive diagnostic capabilities, and widespread adoption of innovative healthcare technologies. Hospitals, physician offices, emergency departments, and other healthcare facilities utilize rapid diagnostic technologies for disease detection and patient monitoring. Demand is supported by the need for timely clinical decisions and efficient management of chronic conditions. Germany's expertise in medical engineering, laboratory diagnostics, sensors, and digital healthcare technologies supports development of sophisticated point of care systems. Continued investment in healthcare technology and decentralized diagnostic capabilities strengthens Germany's position within the European point of care diagnostics market.
The United Kingdom contributes to the point of care diagnostics market through its established healthcare system, strong clinical research capabilities, expanding community healthcare services, and increasing adoption of rapid testing technologies. Point of care diagnostics can help healthcare professionals obtain timely information for infectious diseases, chronic conditions, cardiovascular disorders, and other clinical requirements. Deployment across primary care and community settings can reduce dependence on centralized laboratory testing for appropriate applications. Increasing integration of digital technologies is also supporting more efficient transfer and management of diagnostic information. Continued emphasis on accessible healthcare, rapid diagnosis, and innovative testing technologies supports the United Kingdom's contribution to the European point of care diagnostics market.
Latin America represented 5.25% of the global point of care diagnostics market in 2025, with a market value of USD 2.63 billion. The region is expected to register a CAGR of 7.18% during the forecast period. Growth is supported by improving healthcare infrastructure, increasing demand for accessible diagnostic services, expanding chronic disease management, and greater awareness of early disease detection. Portable testing platforms are particularly valuable for extending diagnostic capabilities to community healthcare facilities and areas with limited access to centralized laboratories. Growing investment in hospitals and diagnostic services is increasing availability of rapid testing technologies. Continued healthcare modernization and adoption of decentralized testing support expansion of the point of care diagnostics market across Latin America.
Brazil is an important contributor to the point of care diagnostics market in Latin America due to its large healthcare system, substantial patient population, expanding diagnostic infrastructure, and growing demand for rapid testing solutions. Point of care technologies are increasingly relevant for infectious disease testing, chronic disease monitoring, emergency diagnostics, and other applications requiring timely results. Portable systems can help expand testing availability across hospitals, clinics, community health centers, and geographically dispersed populations. Increasing development of digital healthcare infrastructure also creates opportunities for connected diagnostic technologies and improved data management. Continued investment in diagnostic accessibility and healthcare modernization reinforces Brazil's importance within the regional point of care diagnostics market.
The Middle East and Africa accounted for 3.45% of the global point of care diagnostics market in 2025, representing a market value of USD 1.73 billion. The region is projected to expand at a CAGR of 6.73% during the forecast period. Market development is supported by improving healthcare infrastructure, growing requirements for infectious disease testing, increasing chronic disease management, and expanding access to diagnostic services. Portable and rapid testing platforms can help healthcare providers extend diagnostic capabilities to locations where centralized laboratory infrastructure remains limited. Investment in hospitals and community healthcare facilities is further improving access to modern diagnostic technologies. These factors support long-term development of the point of care diagnostics market across the region.
The UAE contributes to the point of care diagnostics market within the Middle East and Africa through its modern healthcare infrastructure, sophisticated hospitals, expanding digital health ecosystem, and strong adoption of advanced medical technologies. Healthcare providers increasingly utilize rapid diagnostic platforms to support timely clinical decision-making across hospitals, clinics, emergency departments, and specialized care settings. Development of connected healthcare infrastructure is creating opportunities for diagnostic devices capable of integrating test results with broader patient information systems. Growing emphasis on preventive healthcare and efficient disease management further supports adoption of decentralized testing technologies. Continued investment in medical technology and healthcare digitalization strengthens the UAE's role in the regional point of care diagnostics market.
The point of care diagnostics market is moderately consolidated, with major companies such as Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Danaher, QuidelOrtho, Becton Dickinson (BD), bioMérieux, QIAGEN, Werfen, Nova Biomedical, and EKF Diagnostics competing through rapid testing platforms, molecular diagnostics, immunoassays, and connected diagnostic systems. Competition is increasingly driven by faster turnaround times, portable and easy-to-use devices, multiplex testing, molecular point-of-care platforms, AI-enabled connectivity, and decentralized testing across hospitals, clinics, pharmacies, and home-care settings. Established companies are also using partnerships, acquisitions, regulatory approvals, and product launches to broaden their portfolios and strengthen geographic reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
CRISPR Gene Editing Market Size, Share, Growth, Analysis, 2034
Mass Spectrometry Market Size, Share, Growth, Analysis, 2034
Blood Testing Market Size, Share, Growth, Analysis, Report, 2034
3D Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
3D Bioprinting Market Size, Share, Growth, Analysis, Report, 2034
United Kingdom Epigenetics Market Size, Trends, Top Share and Forecast to 2034
We are featured on:
sales@straitsresearch.com